Deep-pocketed investors have adopted a bearish approach towards Viking Therapeutics (NASDAQ:VKTX), and it’s something market players shouldn’t ignore.…
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment. Further trials needed to confirm efficacy and safety.
Deep-pocketed investors have adopted a bearish approach towards Viking Therapeutics (NASDAQ:VKTX), and it’s something market players shouldn’t ignore.…